A New Symptom of COVID‐19: Loss of Taste and Smell

Gautier, J.-F.; Ravussin, Yann

doi:10.1002/oby.22809

Cited by 199 publications

(191 citation statements)

References 0 publications

Supporting

Mentioning

178

Contrasting

Unclassified

Order By: Relevance

“…26,49 . 48,[50][51][52] Since the existence of such a relationship is likely, it also seems likely that during the COVID-2019 outbreak, those who experience complications such as smell and/or taste…”

Section: Resultsmentioning

confidence: 99%

“…47 These associations of smell and taste dysfunctions and CoV-2 are reliable with case reports relating a patient with SARS with long term anosmia after recovery from respiratory distress, with the observation that olfactory function is usually altered after infection with endemic coronaviruses, and with data indicating that deliberate experimental infection of humans with CoV-2 raises the thresholds at which smells can be sensed. [48][49][50][51][52] A highly published news on this issue came when National Basketball Association player Rudy Gobert trapped the coronavirus, and complained loss of smell and taste. 51 Post-viral anosmia and is one of the leading causes of loss of sense of smell in adults, accounting for up to 40% cases of anostmia.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Anosmia and Ageusia as Initial or Unique Symptoms after SARS-COV-2 Virus Infection

Machado¹,

Gutierrez²

2020

Preprint

View full text Add to dashboard Cite

SARS-CoV-2 (CoV-2) is a coronavirus which is causing the actual COVID-19 pandemic. The disease caused by 2019 new coronavirus (2019-nCoV) was named coronavirus disease-19 (COVID-19) by the World Health Organization in February 2020. Primary non-specific reported symptoms of 2019-nCoV infection at the prodromal phase are malaise, fever, and dry cough. The most commonly reported signs and symptoms are fever (98%), cough (76%), dyspnea (55%), and myalgia or fatigue (44%). Nonetheless, recent reports suggest an association between COVID-19 and altered olfactory and taste functions, although smell seems to be more affected than taste. These associations of smell and taste dysfunctions and CoV-2 are consistent with case reports describing a patient with SARS with long term anosmia after recovery from respiratory distress, with the observation that olfactory function is commonly altered after infection with endemic coronaviruses, and with data demonstrating that intentional experimental infection of humans with CoV-299 raises the thresholds at which odors can be detected. Post-viral anosmia and is one of the leading causes of loss of sense of smell in adults, accounting for up to 40% cases of anosmia. Viruses that give rise to the common cold are well known to cause post-infectious loss, and over 200 different viruses are known to cause upper respiratory tract infections. I reviewed the possible mechanisms of smell and taste loss in COVID-19. I concluded that since the existence of such a relationship is likely, it is highly recommended that those patients who experience complications such as smell and/or taste loss, even as unique symptoms, should be considered as potential SARS-CoV-2 virus carriers.

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

Anosmia and Ageusia as Initial or Unique Symptoms after SARS-COV-2 Virus Infection

Machado¹,

Gutierrez²

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Most of our imported cases had mild disease and would have been difficult to identify if their travel and contact history had not been available [19]. In addition to respiratory symptoms, some cases had neurological symptoms, such as loss of smell or taste [20], or gastrointestinal symptoms like diarrhoea. The clinical presentations of COVID-19 involve multi-organ systems not limited to the respiratory tract.…”

Section: Discussionmentioning

confidence: 99%

Analysis of Imported Cases of COVID-19 in Taiwan: A Nationwide Study

Liu

Chen

Hwang

2020

IJERPH

View full text Add to dashboard Cite

In the early stages of the 2019 novel coronavirus disease (COVID-19) pandemic, containment of disease importation from epidemic areas was essential for outbreak control. This study is based on publicly accessible data on confirmed COVID-19 cases in Taiwan extracted from the Taiwan Centers for Disease Control website. We analysed the characteristics, infection source, symptom presentation, and route of identification of the 321 imported cases that were identified from 21 January to 6 April 2020. They were mostly returned Taiwanese citizens who had travelled to one or more of 37 countries for tourism, business, work, or study. Half of these cases developed symptoms before arrival, most of the remainder developed symptoms 1-13 days (mean 4.0 days) after arrival, and 3.4% never developed symptoms. Three-quarters of the cases had respiratory symptoms, 44.9% had fever, 13.1% lost smell or taste, and 7.2% had diarrhoea. Body temperature and symptom screening at airports identified 32.7% of the cases. Of the remainder, 27.7% were identified during home quarantining, 16.2% were identified via contact tracing, and 23.4% were reported by hospitals. Under the strict enforcement of these measures, the incidence of locally acquired COVID-19 cases in Taiwan remains sporadic. In conclusion, proactive border control measures are effective for preventing community transmission of this disease.

show abstract

“…The clinical manifestations represent a wide spectrum of disease ranging from mild to severe respiratory syndrome influenza-like illness with mainly lower respiratory tract symptoms, complicated by pneumonia and acute respiratory distress syndrome (ARDS), high fever, and headache (10). In many cases, loss of taste and smell and severe gastrointestinal symptoms are reported, as are cardiac problems, with the latter being perhaps secondary to a cytokine storm such as is seen in the more severely affected patients (10)(11)(12). Based on the data from China, approximately 80% of people infected with COVID-19 present with mild to moderate disease that may include pneumonia; about 14% have severe disease with blood oxygen saturation (Յ93%); and 6% are critical, with respiratory failure, septic shock, and/or serious multiple-organ dysfunction or failure (9).…”

mentioning

confidence: 99%

COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions

Triggle

Bansal

Farag

et al. 2020

mSphere

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and first emerged in December 2019 in Wuhan, Hubei province, China. Since then, the virus has rapidly spread to many countries. While the outbreak in China appears to be in decline, the disease has spread across the world, with a daily increase in the number of confirmed cases and infection-related deaths. Here, we highlight (i) the lessons that have been learnt so far and how they will benefit reducing the impact of COVID-19 disease and (ii) an update on the status of drug treatment and vaccine development to prevent COVID-19 and potential future related pandemics. Although the mortality rate is clearly higher than for influenza, the rate does seem to vary from country to country, possibly reflecting differences in how rapidly local health authorities respond to isolate and effectively care for the affected population. Drugs are urgently needed for both prophylaxis and the treatment of severely ill patients; however, no proven effective therapies for SARS-CoV-2 currently exist. A number of drugs that have been approved for other diseases are being tested for the treatment of COVID-19 patients, but there is an absence of data from appropriately designed clinical trials showing that these drugs, either alone or in combination, will prove effective. There is also a global urgency to develop a vaccine against COVID-19, but development and appropriate testing will take at least a year before such a vaccine will be globally available. This review summarizes the lessons learnt so far from the COVID-19 pandemic, examines the evidence regarding the drugs that are being tested for the treatment of COVID19, and describes the progress made in efforts to develop an effective vaccine.

show abstract

A New Symptom of COVID‐19: Loss of Taste and Smell

Cited by 199 publications

References 0 publications

<strong></strong><strong>Anosmia and Ageusia as Initial or Unique Symptoms after SARS-COV-2 Virus Infection</strong>

<strong></strong><strong>Anosmia and Ageusia as Initial or Unique Symptoms after SARS-COV-2 Virus Infection</strong>

Analysis of Imported Cases of COVID-19 in Taiwan: A Nationwide Study

COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions

Contact Info

Product

Resources

About